{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:17:04Z","timestamp":1791515824389,"version":"4.3.4"},"reference-count":51,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>A better understanding of ABL1 kinase domain mutation\u2013independent causes of tyrosine kinase inhibitor (TKI) resistance is needed for BCR::ABL1\u2013positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although TKIs have dramatically improved outcomes, a subset of patients still experiences relapsed or refractory disease. We aimed to identify potential biomarkers of intrinsic TKI resistance at diagnosis in samples from 32 pediatric and 19 adult patients with BCR::ABL1\u2013positive BCP-ALL. Reduced ex\u00a0vivo imatinib sensitivity was observed in cells derived from newly diagnosed patients who relapsed after combined TKI and chemotherapy treatment compared with cells derived from patients who remained in continuous complete remission. We observed that ex\u00a0vivo imatinib resistance was inversely correlated with the amount of (phosphorylated) BCR::ABL1\/ABL1 protein present in samples that were taken at diagnosis without prior TKI exposure. This suggests an intrinsic cause of TKI resistance that is independent of functional BCR::ABL1 signaling. Simultaneous deletions of IKZF1 and CDKN2A\/B and\/or PAX5 (IKZF1plus), as well as deletions of PAX5 alone, were related to ex\u00a0vivo imatinib resistance. In addition, somatic lesions involving ZEB2, SETD2, SH2B3, and CRLF2 were associated with reduced ex\u00a0vivo imatinib sensitivity. Our data suggest that the poor prognostic value of IKZF1(plus) deletions is linked to intrinsic mechanisms of TKI resistance other than ABL1 kinase domain mutations in newly diagnosed pediatric and adult BCR::ABL1\u2013positive BCP-ALL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012162","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T21:16:00Z","timestamp":1708636560000},"page":"1835-1845","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Tyrosine kinase inhibitor resistance in de novo <i>BCR<\/i>::<i>ABL1<\/i>\u2013positive BCP-ALL beyond kinase domain mutations"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-7397","authenticated-orcid":false,"given":"Inge","family":"van Outersterp","sequence":"first","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4848-7789","authenticated-orcid":false,"given":"Judith M.","family":"Boer","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesca","family":"van de Ven","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin E. J.","family":"Reichert","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Boeree","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kruisinga","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester A.","family":"de Groot-Kruseman","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Escherich","sequence":"additional","affiliation":[{"name":"2Department of Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Sijs-Szabo","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita W.","family":"Rijneveld","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique L.","family":"den Boer","sequence":"additional","affiliation":[{"name":"1Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"5Department of Pediatric Oncology and Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"issue":"2 Suppl 2","key":"2024042218552542900_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"issue":"9","key":"2024042218552542900_bib2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"issue":"3","key":"2024042218552542900_bib3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","article-title":"Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group","volume":"112","author":"Burmeister","year":"2008","journal-title":"Blood"},{"issue":"14","key":"2024042218552542900_bib4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Aric\u00f2","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"2024042218552542900_bib5","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","article-title":"Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005","volume":"28","author":"Aric\u00f2","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024042218552542900_bib6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","article-title":"Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study","volume":"16","author":"Takeuchi","year":"2002","journal-title":"Leukemia"},{"issue":"12","key":"2024042218552542900_bib7","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"issue":"9","key":"2024042218552542900_bib8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024042218552542900_bib9","first-page":"175","article-title":"Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor","volume":"27","author":"Weiner","year":"2011","journal-title":"J\u00a0ECT"},{"issue":"12","key":"2024042218552542900_bib10","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol"},{"issue":"22","key":"2024042218552542900_bib11","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024042218552542900_bib12","first-page":"e510","article-title":"Final results of CA180-372\/COG AALL1122 phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly-diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (PH plus ALL)","volume":"10","author":"Hunger","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"2024042218552542900_bib13","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024042218552542900_bib14","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","article-title":"Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"19","author":"Lee","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"2024042218552542900_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024042218552542900_bib16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study","volume":"109","author":"de Labarthe","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2024042218552542900_bib17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3390\/cancers14071805","article-title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"14","author":"Saleh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2024042218552542900_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"2024042218552542900_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2012.09039.x","article-title":"Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ALL: a Children\u2019s Oncology Group (COG) study","volume":"157","author":"Chang","year":"2012","journal-title":"Br J Haematol"},{"issue":"23","key":"2024042218552542900_bib20","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood.V126.23.2622.2622","article-title":"Clonal evolution and lack of BCR-ABL1 mutations in pediatric Ph+ ALL patients resistant\/refractory to imatinib treatment","volume":"126","author":"Cazzaniga","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2024042218552542900_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/leu.2012.5","article-title":"Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia","volume":"26","author":"Pfeifer","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"2024042218552542900_bib22","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1038\/s41598-022-17271-3","article-title":"Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA","volume":"12","author":"S\u00e1nchez","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"2024042218552542900_bib23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2024042218552542900_bib24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2021.279807","article-title":"Detection of ABL1 kinase domain mutations in therapy-na\u00efve BCR-ABL1-positive acute lymphoblastic leukemia","volume":"107","author":"Baer","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"2024042218552542900_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2010.034173","article-title":"Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis","volume":"96","author":"Soverini","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"2024042218552542900_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2024042218552542900_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"23","key":"2024042218552542900_bib28","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In\u00a0vitro and in\u00a0vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"issue":"5682","key":"2024042218552542900_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"11","key":"2024042218552542900_bib30","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood"},{"issue":"31","key":"2024042218552542900_bib31","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"2024042218552542900_bib32","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1200\/JCO.2023.41.16_suppl.10017","article-title":"Preliminary results from the first-in-child phase II trial (ITCC-054\/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML)","volume":"41","author":"Pennesi","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024042218552542900_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024042218552542900_bib34","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2024042218552542900_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ph15010024","article-title":"The role of LNK (SH2B3) in the regulation of JAK-STAT signalling in haematopoiesis","volume":"15","author":"Morris","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"2024042218552542900_bib36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024042218552542900_bib37","doi-asserted-by":"crossref","first-page":"e12611","DOI":"10.1111\/cpr.12611","article-title":"Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells","volume":"52","author":"Sheng","year":"2019","journal-title":"Cell Prolif"},{"issue":"2","key":"2024042218552542900_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3324\/haematol.2018.196055","article-title":"Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"104","author":"Fedullo","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2024042218552542900_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"issue":"10","key":"2024042218552542900_bib40","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3324\/haematol.2009.020792","article-title":"The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party","volume":"95","author":"Iacobucci","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"2024042218552542900_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41408-021-00570-9","article-title":"Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes","volume":"11","author":"Studd","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024042218552542900_bib42","doi-asserted-by":"crossref","first-page":"979060","DOI":"10.3389\/fimmu.2022.979060","article-title":"The development and function of CD11c(+) atypical B cells - insights from single cell analysis","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2024042218552542900_bib43","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3324\/haematol.2020.249094","article-title":"Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia","volume":"106","author":"Zaliova","year":"2021","journal-title":"Haematologica"},{"issue":"18","key":"2024042218552542900_bib44","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J\u00a0Med Chem"},{"issue":"2","key":"2024042218552542900_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","article-title":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","volume":"22","author":"Braendstrup","year":"2020","journal-title":"Cytotherapy"},{"issue":"5","key":"2024042218552542900_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024042218552542900_bib47","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"issue":"16","key":"2024042218552542900_bib48","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024042218552542900_bib49","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"2024042218552542900_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.HS9.0000844300.04335.af","article-title":"P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL","volume":"6","author":"Chiaretti","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"2024042218552542900_bib51","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1835\/2222931\/blooda_adv-2023-012162-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1835\/2222931\/blooda_adv-2023-012162-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T18:55:50Z","timestamp":1713812150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1835\/515035\/Tyrosine-kinase-inhibitor-resistance-in-de-novo"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012162","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]}}}